| Hans-Günter Meyer-Thompson | Hepatitiden
Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
Madden A, Hopwood M, Neale J, Treloar C (2018)
PLoS ONE 13(11): e0207226. doi.org/10.1371/journal.pone.0207226
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0207226